Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.97 Analyst target: $10.09 Upside: 154.16%
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania.
See the full interactive analysis & chart →Informational only — not investment advice.